(Q38122265)

29 August 2017

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer (English)

1 reference

29 August 2017

1 reference

1 reference

Christen L Walters

1

1 reference

29 August 2017

Rebecca C Arend

2

1 reference

29 August 2017

Deborah K Armstrong

3

1 reference

29 August 2017

R Wendel Naumann

4

1 reference

29 August 2017

Ronald D Alvarez

5

1 reference

29 August 2017

language of work or name

English

0 references

publication date

14 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

131

1 reference

29 August 2017

493-498

1 reference

29 August 2017

2

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

29 August 2017

1 reference

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Rethinking ovarian cancer: recommendations for improving outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Bevacizumab in the treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Folate and carcinogenesis: an integrated scheme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Folate-mediated one-carbon metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

inferred from DOI database lookup

7 January 2021

based on heuristic

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Mechanism of N10-formyltetrahydrofolate synthetase derived from complexes with intermediates and inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Endocytosis of GPI-linked membrane folate receptor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Insilco analysis of functionally important residues in folate receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Overexpression of folate binding protein in ovarian cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Monoclonal antibodies in gynecological cancer: a critical point of view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Folate-targeted chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.080

10.1016/J.YGYNO.2013.07.080

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference